US Pharma MarketingThe ‘search for a magic bullet has faded’ in cancer immunotherapy. Here’s what’s next
The two best-selling checkpoint inhibitors — Merck’s Keytruda and Bristol Myers Squibb’s Opdivo — are now approaching their patent cliffs. And the biopharma industry is coming to terms with the fact that it may not be able to repeat its success. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy…
The two best-selling checkpoint inhibitors — Merck’s Keytruda and Bristol Myers Squibb’s Opdivo — are now approaching their patent cliffs. And the biopharma industry is coming to terms with the fact that it may not be able ...
Source: Endpoints News